Imaging Study of a CAIX Binder in Metastatic Clear Cell RCC.

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: EARLY_PHASE1

Enrollment: 10

Sponsor: RayzeBio, Inc.

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of a novel Carbonic Anhydrase IX (CAIX) Binder in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).

Eligibility Criteria

Inclusion Criteria: * At least 18 years old at the time of signing the informed consent form (ICF). * Biopsy proven metastatic clear cell renal cell carcinoma (RCC) Exclusion Criteria: * Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides * Women of Childbearing Potential that are pregnant or breastfeeding. Note: Additional criteria may apply and will be assessed by the study site

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07671417). StuddyBuddy aggregates publicly available trial information.